Expertise in
5
conditions

Dr. Jennifer Soung

Dermatology
J Robert West MD Inc
1125 E 17th St, Suite W248, 
Santa Ana, CA 
Expertise in
5
conditions
J Robert West MD Inc
1125 E 17th St, Suite W248, 
Santa Ana, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jennifer Soung is a Dermatologist in Santa Ana, California. Dr. Soung is highly rated in 5 conditions, according to our data. Her top areas of expertise are Plaque Psoriasis, Psoriasis, Atopic Dermatitis, and Alopecia Areata.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

J ROBERT WEST MD INC
1125 E 17th St, Suite W248, Santa Ana, CA 92701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: June 15, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: January 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

27 Total Publications

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.
Journal: JAMA dermatology
Published: May 07, 2025
Similar Doctors
Christiane S. Querfeld
Expertise in
12
conditions
Dr. Christiane S. Querfeld
Dermatology
Expertise in
12
conditions
Dr. Christiane S. Querfeld
Dermatology

City Of Hope Medical Foundation

1601 Avocado Ave, 
Newport Beach, CA 
 (10.1 mi)
949-763-2204
Languages Spoken:
English
Offers Telehealth

Christiane Querfeld is a Dermatologist in Newport Beach, California. Dr. Querfeld is highly rated in 12 conditions, according to our data. Her top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.

Expertise in
12
conditions
Dr. Natasha A. Mesinkovska
Dermatology
Expertise in
12
conditions
Dr. Natasha A. Mesinkovska
Dermatology

Uci Department Of Dermatology

101 The City Dr S, 
Orange, CA 
 (2.8 mi)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Natasha Mesinkovska is a Dermatologist in Orange, California. Dr. Mesinkovska is highly rated in 12 conditions, according to our data. Her top areas of expertise are Autosomal Recessive Hypotrichosis, Alopecia Areata, Alopecia Universalis, and Vitiligo.

Expertise in
13
conditions
Dr. Sergei A. Grando
Dermatology
Expertise in
13
conditions
Dr. Sergei A. Grando
Dermatology

Uci Department Of Dermatology

101 The City Dr S, 
Orange, CA 
 (2.8 mi)
714-456-7004
Languages Spoken:
English
Offers Telehealth

Sergei Grando is a Dermatologist in Orange, California. Dr. Grando is highly rated in 13 conditions, according to our data. His top areas of expertise are Pemphigus Vulgaris, Pemphigus, Pemphigus Foliaceus, and Bullous Pemphigoid.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Soung's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile